{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(7)"],"submitter":["Jeyaraman M"],"pubmed_abstract":["The contagiosity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has startled mankind and has brought our lives to a standstill. The treatment focused mainly on repurposed immunomodulatory and antiviral agents along with the availability of a few vaccines for prophylaxis to vanquish COVID-19. This seemingly mandates a deeper understanding of the disease pathogenesis. This necessitates a plausible extrapolation of cell-based therapy to COVID-19 and is regarded equivalently significant. Recently, correlative pieces of clinical evidence reported a robust decline in lymphocyte count in severe COVID-19 patients that suggest dysregulated immune responses as a key element contributing to the pathophysiological alterations. The large granular lymphocytes also known as natural kille"],"journal":["Heliyon"],"pagination":["e07635"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8294777"],"repository":["biostudies-literature"],"pubmed_title":["Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19."],"pmcid":["PMC8294777"],"pubmed_authors":["Jain R","Chellappan DK","Channaiah Anudeep T","Jeyaraman M","Dilip SJ","Kesari KK","Dholpuria S","Dua K","Kumar D","Dureja H","Ojha S","Muthu S","Jha NK","Gupta G","Jha SK","Sushmitha ES","Bapat A","Gulati A","Singh SK"],"additional_accession":[]},"is_claimable":false,"name":"Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.","description":"The contagiosity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has startled mankind and has brought our lives to a standstill. The treatment focused mainly on repurposed immunomodulatory and antiviral agents along with the availability of a few vaccines for prophylaxis to vanquish COVID-19. This seemingly mandates a deeper understanding of the disease pathogenesis. This necessitates a plausible extrapolation of cell-based therapy to COVID-19 and is regarded equivalently significant. Recently, correlative pieces of clinical evidence reported a robust decline in lymphocyte count in severe COVID-19 patients that suggest dysregulated immune responses as a key element contributing to the pathophysiological alterations. The large granular lymphocytes also known as natural kille","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2025-04-05T00:48:51.012Z","creation":"2022-02-11T11:15:17.69Z"},"accession":"S-EPMC8294777","cross_references":{"pubmed":["34312598"],"doi":["10.1016/j.heliyon.2021.e07635"]}}